amantadine / Generic mfg. - LARVOL DELTA

Clinical and etiological characteristics of catatonic disorder due to another medical condition: A retrospective study from a tertiary care center. (PubMed, Clin Neurol Neurosurg) - "Catatonic disorder due to another medical condition appears to present with diverse underlying causes and clinical manifestations. Although benzodiazepines are generally considered the first-line treatment, additional interventions were often needed. These findings underline the importance of clinical awareness and timely management, while further research is required to better understand prognostic factors and to guide treatment strategies."

Journal • Retrospective data • CNS Disorders • Immunology

Levodopa-induced dyskinesia in Parkinson's disease: an updated review of pharmacological treatments. (PubMed, Front Aging Neurosci) - "Despite decades of investigation, only amantadine has been established as the standard FDA-approved treatment, while istradefylline provides a complementary non-dopaminergic option. Most other candidate agents-including memantine, clozapine, and serotonergic or noradrenergic modulators-have shown inconsistent efficacy or safety limitations, underscoring persistent translational challenges between preclinical promise and clinical outcomes...Potential complementary pathways, including Traditional Chinese Medicine (TCM), are also briefly noted as alternative directions. By linking mechanistic insights with therapeutic evidence, this review provides an updated framework for optimizing LID management and guiding future research directions."

Journal • Review • CNS Disorders • Movement Disorders • Parkinson's Disease

Enhancing amantadine delivery through PLGA micelles: a novel approach using oleic acid and Pluronic F68 for sustained release and reduced toxicity. (PubMed, RSC Adv) - "This formulation enables controlled release, potentially reducing administration frequency while extending therapeutic efficacy. The novelty of this study lies in the combination of Pluronic F68 and oleic acid surfactants, enhancing drug stability and delivery efficiency, making it a promising approach for improving amantadine delivery in Parkinson's treatment."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Neurostimulant Use and Cognitive Outcomes in Patients with Acute, Severe Traumatic Brain Injury. (PubMed, Neurocrit Care) - "Nearly a third of patients with severe TBI received NS. Patients receiving NS were more injured and had worse disability at discharge compared to non-NS patients. However, among patients who received NS, treatment within 7 days was associated with an increased odds of a favorable outcome."

Journal • CNS Disorders • Cognitive Disorders • Developmental Disorders • Vascular Neurology

Intervention of early use of amantadine on the outcome of patients with diquat poisoning (ChiCTR) - P=N/A | N=112 | Not yet recruiting | Sponsor: The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University

New trial

Noninvasive neuroregulation of the whole cycle of consciousness impairment rehabilitation based on multimodal images (ChiCTR) - P=N/A | N=100 | Not yet recruiting | Sponsor: Ankang Central Hospital; Ankang Central Hospital

New trial

REVOLUTIONIZING NEUROREHABILTIATION: A SCOPING REVIEW OF THE PROMISING ROLE OF AMANTADINE IN THE RECOVERY OF PATIENTS WITH NON-TRAUMATIC BRAIN INJURY (WSC 2025) - "Amantadine accelerates the neurologic recovery of patients with disorder of unconsciousness secondary to nontraumatic brain injuries. Future studies may conduct meta-analysis, systematic reviews, and randomized controlled trials of amantadine in nontraumatic brain injury patients to further strengthen the promising role of amantadine in neurorehabilitation."

Clinical • Review • CNS Disorders • Movement Disorders • Parkinson's Disease • Vascular Neurology

Discovery of adamantane-based α-hydroxycarboxylic acid derivatives as potent M2-S31N blockers of influenza A virus. (PubMed, Bioorg Chem) - "The clinical discontinuation of amantadine and rimantadine due to widespread drug resistance highlights the need for new chemical entities that target the M2 ion channel to fight influenza outbreaks and pandemics...Its activity was comparable to that of oseltamivir...Furthermore, the ADMET properties were calculated using the QikProp of the Schrödinger suite, which showed desirable pharmacokinetic characteristics for further development. This work expands the chemical space of adamantane-based compounds and opens up a new direction for the development of anti-influenza drugs with diverse structures."

Journal • Infectious Disease • Influenza • Respiratory Diseases

Shepherin II Gene Synthesis and Peptide Characterization: E. coli Expression, Purification, and Antiviral Activity. (PubMed, Protein Pept Lett) - "This study demonstrated the feasibility of recombinant shepherin II production and assessed its antiviral activity. However, the limited selectivity index of shepherin II remains a challenge that needs to be addressed through molecular modification or alternative delivery strategies to improve its clinical potential."

Journal • Infectious Disease • Inflammation

Beyond Infections: A Case Report on the Identification of Neuroleptic Malignant Syndrome (NMS) in a Complex Clinical Context. (PubMed, Clin Case Rep) - "A 59-year-old woman with kidney failure and Parkinson's disease developed fever, rigidity, and cognitive decline after taking antipsychotics and the discontinuation of memantine and amantadine. Despite a high clinical suspicion of nosocomial infections (NIs), no evidence of infection was identified. Thus, neuroleptic malignant syndrome (NMS) was highly suspected."

Journal • CNS Disorders • Infectious Disease • Movement Disorders • Parkinson's Disease • Renal Disease

HIGH ALTITUDE-ASSOCIATED INTRACRANIAL HEMORRHAGE (CHEST 2025) - "Empiric Amantadine was started by the neurology team with the plan to await neurologic recovery...Treatment is aimed at symptom improvement by descending at least 1000 m or until improved symptoms Other treatment options include dexamethasone, acetazolamide supplemental oxygen or a portable hyperbaric chamber High altitude cerebral edema with intracranial hemorrhage is a very rare process and can be potentially fatal. This case highlights the gravity of HACE and the importance of early recognition for prompt treatment. Further investigation is warranted to explore the pathophysiology of HACE and intracranial hemorrhage."

Anesthesia • Cerebral Hemorrhage • CNS Disorders • Epilepsy • Hematological Disorders • Pulmonary Disease • Urinary Incontinence • Urology

ARTERY OF PERCHERON INFARCT: A DIAGNOSTIC DILEMMA (CHEST 2025) - "Key treatments were permissive hypertension to maintain cerebral perfusion, aspirin to prevent secondary strokes, and slow arousal with neuro stimulants such as amantadine. The case shows the diagnostic and treatment challenges that arise from AOP infarction, a rare and poorly understood cause of delusional brain apnea and coma. Intense unresponsiveness and an asymmetric pupillary response at the outset may raise the concern for a broad range of differential diagnosis and usual imaging with a CTH and CTA head may completely unrevealing. Hence, MRI with diffusion-weighted imaging is needed for early and precise detection."

Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Congestive Heart Failure • Heart Failure • Hematological Disorders • Hypertension • Ischemic stroke

BEYOND THE TREMORS: A RARE CASE OF DYSKINESIA-HYPERPYREXIA SYNDROME IN ADVANCED PARKINSON'S DISEASE (CHEST 2025) - "CASE PRESENTATION: We present a case of a 71-year-old female with advanced PD on high-dose levodopa/carbidopa and amantadine, who presented with acute hyperpyrexia (Tmax 106.7◦F), severe generalized dyskinesia, and encephalopathy...She received benzodiazepines (lorazepam and midazolam) and was carefully restarted on her home PD medications to prevent withdrawal... This case underscores the importance of early recognition of DHS as a distinct entity in hyperpyrexic PD patients to ensure timely and appropriate treatment."

Clinical • Metastases • Acute Kidney Injury • Breast Cancer • CNS Disorders • Diabetes • Hypertension • Infectious Disease • Influenza • Metabolic Disorders • Movement Disorders • Nephrology • Parkinson's Disease • Pulmonary Disease • Renal Disease • Respiratory Diseases • Solid Tumor • Type 2 Diabetes Mellitus

Drug target residue selection for synthetic cannabinoids monitoring by wastewater-based epidemiology: case study of the AKB-48F (4F-ABINACA or 4F-ABUTINACA). (PubMed, Environ Sci Pollut Res Int) - "The two AKB-48F most relevant metabolites identified are the product of amantadine core hydroxylation and dihydroxylation, with respectively 26 and 29% of peak intensity. Both metabolites are expected not to be significantly altered by sewage conditions, considering their anticipated transit duration and, thus, could be relevant biomarkers for wastewater-based epidemiological studies."

Journal

Antiviral drugs for seasonal influenza for 2025-2026. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Infectious Disease • Influenza • Respiratory Diseases

Use of Influenza Antivirals to Prevent Transmission. (PubMed, J Infect Dis) - "During pandemic responses, antiviral prophylaxis could play an important role, as demonstrated by the use of amantadine in the 1968-1969 influenza A(H3N2) pandemic and oseltamivir during the 2009-2010 influenza A(H1N1)pdm09 pandemic. Future research directions include innovative therapies and combination treatments. Continued research and stewardship are crucial to optimize antiviral impact."

Journal • Infectious Disease • Influenza • Respiratory Diseases

Repetitive transcranial magnetic stimulation targeting the dorsolateral prefrontal cortex promotes recovery of consciousness in patients with disorders of consciousness: a meta-analysis of randomized controlled trials. (PubMed, J Neurol) - "rTMS targeting the DLPFC can significantly promote recovery of consciousness in patients with DoC, with both 10 Hz and 20 Hz frequencies demonstrating clinical potential. Future large-sample, standardized RCTs are warranted to reduce heterogeneity and identify biomarkers for predicting treatment response, thereby facilitating the precision application of rTMS in DoC."

Clinical • Journal • Retrospective data • Review • CNS Disorders • Vascular Neurology

Unraveling the Variability in Amantadine Response for Levodopa-Induced Dyskinesias: The Impact of Clinical and Genetic Factors (MDS Congress 2025) - "Our data indicate that the efficacy and tolerability of amantadine are influenced by various clinical factors, and patients may respond differently based on the presence of certain genetic variants. The generated PRS will be assessed and their potential association with amantadine response will be presented at the conference."

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Trihexyphenidyl as a Treatment for Severe Freezing of Gait in Parkinson's Disease: A Case Report (MDS Congress 2025) - "Prior treatments—including Sinemet, Rotigotine, Ropinirole, Clonazepam, Amantadine, and Rasagiline—were ineffective and caused additional symptoms like tremors and fatigue. To date, no published case studies have demonstrated significant improvement in a patient's freezing of gait (FoG) with trihexyphenidyl (Artane), except for a single case reported in 2020 (1). That study described a patient with a FoG-like gait disturbance characterized by direction-associated FoG occurring exclusively during forward walking, who experienced gait improvement with trihexyphenidyl. However, the patient's leg symptoms were more consistent with task-specific dystonia, as subsequent surface electromyography (EMG) studies revealed dystonic co-contraction in the leg during forward walking in the OFF-state, but not during backward walking or side-stepping, supporting a diagnosis of task-specific dystonia."

Case report • Clinical • CNS Disorders • Dystonia • Movement Disorders • Parkinson's Disease

The Clinical Case of Acute Comorbidities in Parkinson's Disease (MDS Congress 2025) - " At first the patient received levodopa-carbidopa 125 mg 6 times per day...No increase in visuospatial disorders frequency occurred during combination of Amantadine and Levodopa due to plateau of Clozapine concentration and positive dynamics of hematoma resolution... This case shows the role of comorbide pathologies which can both decompensate PD and be the reason of similar symptoms. When assessing existing symptoms, progression/decompensation of the disease, concomitant and possible competing pathology should be considered Triventricular hydrocephalia on MRI Right parahyppocampal gyrus haemorrhage on CT"

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease • Psychomotor Agitation • Ventriculomegaly

Whispers of Hope Motor and Psychiatric Recovery in Fahr's Disease with High-Frequency rTMS: A Case Report (MDS Congress 2025) - "Partial symptomatic relief was achieved with levodopa and amantadine, however depressive symptoms persisted... This case suggests that rTMS may provide dual benefits for both psychiatric and motor symptoms in Fahr's disease. Given the rarity of FD and the lack of disease-modifying treatments, further studies are warranted to explore its long-term efficacy and optimize stimulation protocols. Table 1."

Case report • Clinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Depression • Mental Retardation • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Trends on recruitment and retention in Parkinson's Disease modification trials (MDS Congress 2025) - "54.5% recruited levodopa-treated patients, 22.7% drug-naïve, and others trialed mixed populations of drug-naïve and treated (with levodopa, MAO-B inhibitors, amantadine or anticholinergics)... Participants of PD DMT trials demonstrate high commitment, with low attrition rates. Screen failure rates vary but seldom exceed 50%, primarily influenced by patient decision. Enhancing patient education on trials and investigational agents through consistent investigator-patient communication will help boost patient confidence on trial participation."

CNS Disorders • Movement Disorders • Parkinson's Disease

Pathogenic TBK1 Mutation Associated with Multiple System Atrophy-Like Phenotype (MDS Congress 2025) - "Trials of carbidopa/levodopa, ropinirole, pramipexole, and amantadine had minimal clinical benefit. Exome sequencing revealed a heterozygous nonsense mutation (c.1335 G>A; p.W445*) in exon 11 of TBK1, predicted to cause protein truncation or nonsense-mediated decay. This specific mutation has been reported in patients with FTD and one case of FTD-CBS (4,5). Soon after, patient developed severe stridor with vocal cord paralysis and worsening orthostatic hypotension requiring hospitalization and ultimately declined life-sustaining interventions."

Alzheimer's Disease • Ataxia • Behavior Disorders • CNS Disorders • Dementia • Dystonia • Frontotemporal Lobar Degeneration • Mental Retardation • Movement Disorders • Multiple System Atrophy • Parkinson's Disease • Progressive Supranuclear Palsy • Psychiatry • TBK1

Risk factors for central nervous system side effects of amantadine (MDS Congress 2025) - "The risk factors for amantadine CNS side effects were elderly patients, amantadine dosage, and reduced renal function. The threshold blood level of amantadine for CNS side effects was 1562ng/ml."

Adverse events • Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Parkinsonism after Post-Anoxic Brain Injury (MDS Congress 2025) - "Carbidopa-levodopa and istradefylline offered little benefit for FOG. Patient experienced partial improvement in gait with amantadine... Parkinsonism is a rare manifestation that may be encountered in post-anoxic patients with basal ganglia injury. Differences in symptoms and response to medications may be due to extent of basal ganglia damage. DaT scan may be considered for further verification of parkinsonism in anoxia."

CNS Disorders • Movement Disorders • Parkinson's Disease • Vascular Neurology